

α 41 β 7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α -chain (TAC).

¹²³
39. (New) The conjugate of claim 39 wherein the nonproteinaceous polymer molecule is polyethylene glycol (PEG).

¹²⁴
40. (New) The conjugate of claim 39 wherein the antibody fragment is selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, and F(ab')₂.

¹²⁷
41. (New) The conjugate of claim 39 wherein the antibody fragment is selected from the group consisting of Fab, Fab' and Fab'-SH modified by one PEG molecule.

¹²⁸
42. (New) The conjugate of claim 41 wherein the PEG molecule has an average molecular weight of at least 30 kD.

31 ¹²⁹
43. (New) The conjugate of claim 38 wherein the apparent molecular weight of the conjugate is at least about 800 kD.

¹³⁰
44. (New) The conjugate of claim 38 wherein the apparent molecular weight of the conjugate is at least about 1,800 kD.

¹³¹
45. (New) The conjugate of claim 38 comprising the antigen binding site of HER2.

¹³²
46. (New) The conjugate of claim 38 comprising the antigen binding site of

DC20.

Remarks

The foregoing claims are fully supported by the specification, and do not add new matter. New claim 38 finds support, for example, at page 10, lines 22-28 to page 11, lines 1-2; page 47, line 22-25; and page 48, lines 3-9. New claim 39 finds support, for example, at page 58, line 11. New claim 40 finds support, for example, at page 50, line 19. New claim 41 finds support, for example, at page 58, lines 3-5. New claim 42 finds support, for example, at page 58, line 15. New claim 43 finds support, for example, at page 43, line 11. New claim 44 finds support, for example, at page 43, lines 12-13. New claim 45 finds